CPMV pre-revenue biotech warns of going concern; $53K cash, $7.2M liabilities

Mosaic ImmunoEngineering, Inc. (PINK: CPMV) - development-stage biotech. No product revenues. Filing: Form 10-Q for quarter ended June 30, 2025. Management warns of substantial doubt about the company's ability to continue as a going concern.

Quick snapshot - what's happening inside

- Company remains pre-revenue and highly reliant on outside financing; no commercial sales reported.
- Management reduced operating activity and payroll commitments versus the prior year, lowering cash burn.
- A Binding Term Sheet with Oncotelic (potential pipeline acquisition) expired on June 30, 2025 - the planned equity-for-assets deal did not close in the period disclosed.
- Key liabilities are concentrated in accrued compensation and convertible debt; several related-party arrangements and deferred consulting obligations remain on the books.

Key facts & statistics (as reported)

- Cash and cash equivalents (June 30, 2025): $53,583 (Dec 31, 2024: $115,019).
- Total assets: $57,699 (Dec 31, 2024: $141,611).
- Total liabilities: $7,199,221 (Dec 31, 2024: $6,929,785).
- Total current liabilities: $5,770,341.
- Accrued compensation: $4,011,998.
- Convertible notes, net: $1,428,880.
- Loan payable: $200,000.
- Stockholders' deficit (June 30, 2025): $(7,141,522) (Accumulated deficit: $(9,191,668)).
- Common shares issued and outstanding: 7,242,137 (as of Aug 18, 2025).
- Three months ended June 30, 2025 - Net loss: $(172,028) vs $(293,717) in Q2 2024.
- Six months ended June 30, 2025 - Net loss: $(353,348) vs $(582,209) in H1 2024.
- Basic & diluted loss per share: $(0.02) for Q2 2025; $(0.05) for six months 2025.
- Cash used in operating activities (six months ended June 30, 2025): $(61,436) vs $(207,444) in 2024.
- Other income (six months): $14,000 (advisory services to Oncotelic).

Positive aspects of the income statement / operations

- Operating expenses decreased significantly year-over-year: Total operating expenses for Q2 2025 were $148,854 vs $274,302 in Q2 2024 (largely due to lower payroll/time commitments).
- R&D spending fell (Q2 2025: $16,006 vs Q2 2024: $60,707), indicating near-term cost control.
- Net loss narrowed vs prior year periods (both quarterly and year-to-date), demonstrating reduced cash burn from operations.
- Cash used in operations improved materially: $(61,436) in H1 2025 vs $(207,444) in H1 2024 - driven by increases in accrued compensation (non-cash) and lower cash expenses.

Negative aspects of the income statement / risks

- No revenues reported; other income is immaterial ($14,000 in H1 2025).
- Large non-cash interest accretion on convertible notes remains (non-cash interest expense: $18,282 in Q2 2025; $36,365 for six months).
- Accrued compensation is a very large liability ($4,011,998) relative to assets and cash on hand - presents potential cash drag if payments accelerate.
- Despite expense reductions, net loss remains material: $(353,348) for six months ended June 30, 2025.
- Stockholders' deficit of $(7.14M) and accumulated deficit of $(9.19M) indicate entrenched losses and equity erosion.
- Cash runway is extremely tight - $53,583 on hand and management explicitly states cash will not be sufficient through the next 12 months without additional financing (substantial doubt about going concern).
- Convertible notes and the $200,000 note payable create potential dilution (conversion features) or near-term cash obligations tied to financing triggers; conversion math and anti-dilution provisions (Series B preferred) add complexity to shareholder outcomes.

Operational & governance highlights to monitor

- Binding Term Sheet with Oncotelic expired June 30, 2025 - acquisition / pipeline buildout remains uncertain.
- Several related-party convertible note investments and deferred consulting arrangements exist; related-party exposure is material and should be watched closely.
- No material share-based compensation expense in 2025 quarter; RSUs remain reserved (510,513 nonvested RSUs outstanding).
- Management actions: CEO Steven King assumed principal financial officer duties after CFO resignation (noted subsequent events) - watch for staffing & control changes.

Bottom line / investor takeaway

- Mosaic ImmunoEngineering, Inc. (PINK: CPMV) is a pre-revenue, development-stage biotech with sharply reduced operating expenses but extremely limited liquidity and a large accrued compensation liability. The company has narrowed losses and lowered cash burn relative to 2024, which is constructive, but the balance sheet shows significant liabilities, convertible debt, and a stockholders' deficit. Management's own disclosure flags substantial doubt about going concern absent new financing. For investors this remains a high-risk, highly dilutive situation that depends on successful capital raises or a material strategic transaction (which, to date, has not closed).

Monitor next steps: cash balance updates, any definitive financing or M&A announcements, conversions or waivers related to convertible notes, and progress on pipeline acquisitions or licensing.